Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia (PLEASURE)

AstraZeneca

Status: Completed

Conditions: Schizophrenia

Study type: Observational

Funder types: Industry

Identifiers

NCT01160679

NIS-NKR-SER-2010/1

Details and patient eligibility

About

This prospective, multi-center, 12 weeks naturalistic NIS trial will be conducted in 25 hospitals in naturalistic treatment setting. There will be no experimental component associated with this study and all observational activities have to be part of routine care visit: baseline (week 0), week 4 and week 12.

Enrollment: 231 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented clinical diagnosis of schizophrenia meeting the Diagnostic and Statistical Manual of Mental Disorders,(DSM-IV-TR) criteria
• Patients who already take one atypical at inclusion it is started at least 1 week and up to 4 weeks before the inclusion

Exclusion criteria

• Meeting the criteria for any other (than schizophrenia) DSM-IV Axis I
• Patients with antipsychotic combinations (more than two agents)
• Patients who are already on any mood stabilizers and antidepressant
• Known lack of response to clozapine or treatment with clozapine within 4 weeks prior to enrollment
• Patients who have been treated with antipsychotics in depot formulations for the last two months
• Previous enrollment or randomisation of treatment in the present NIS
• Patients who had participated in other clinical trials within 4 weeks prior to enrollment period
• Pregnant women or women who are breast-feeding